FVR, Seinäjoen rokotetutkimusklinikka

Research site

Finland Kauppatori 1-3, Torikeskus 2krs, 60100 Seinajoki, Finland

1 trial recruiting
Pneumococcal immunisation
Children and adolescents

About Specializations

FVR, Seinäjoen rokotetutkimusklinikka in Seinajoki, Finland specialises in clinical trials of conditions such as Pneumococcal immunisation, and other specialisations. This site conducts important research.

Pneumococcal immunisation

Main research areas of the site

Bacterial Infections and Mycoses Research

The clinic in Seinäjoki focuses on bacterial infections and mycoses, with a special emphasis on preventing pneumococcal disease through vaccination.

Safety assessment of an expanded pneumococcal vaccine
Immune response profiling in pediatric subjects
Evaluation of tolerability in healthy infants

These studies aim to confirm that the new PG4 vaccine is safe and well‑tolerated, supporting broader immunisation programs for children and adolescents.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Kauppatori 1-3, Torikeskus 2krs60100 SeinajokiFinland

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 1

More sites in Seinajoki Finland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

2 clinical trials

Pneumococcal immunisation

Recruiting

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Finland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Pneumococcal immunisation

Not yet recruiting

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Finland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites